Immunization with Trichophyton verrucosum Vaccine in Hunter/Jumper and Dressage Horses with Naturally Occurring Trichophyton equinum Infection: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

The aim of the current study was to investigate the efficacy of Trichophyton verrucosum vaccine in hunter/jumper and dressage horses with trichophytosis caused by Trichophyton equinum (cross immunity). A total of 25 hunter/jumper and dressage horses between the ages of 2 and 14 years, naturally infected with Trichophyton equinum, were enrolled and randomly assigned to either a placebo or an intramuscular lyophilized Trichophyton verrucosum vaccine group. Clinical evaluations were done by the same investigator, who scored clinical healing at the beginning, during, and at the end of the treatment and was blinded to allocation to the groups. At the end of the trial, vaccine treatment significantly decreased the investigator's clinical scores (P < .001), and no significant changes were detected in the placebo treatment group. In all of the horses vaccinated, the lesions improved gradually within 7 to 12 days after vaccination. Complete clinical remission was detected within 28 to 42 days, and all treated horses became culture negative within 25 days of starting treatment. No clinical healing was observed in nine untreated control horses throughout the study. No recurrence was observed in treated horses within 10 months after therapy. Results of the current study indicate that inactivated Trichophyton verrucosum vaccine may be a safe and effective therapy for horses with Trichophyton equinum infection.